Biocartis

📖 Publication News from the UK Finall et al. (2022) compare NGS to Idylla™ EGFR Mutation Test (CE-IVD*) and illustrate the importance of rapid biomarker testing in NSCLC ❗ 6% of the patients died before the NGS report was available ❗18% of the patients experienced rapid clinical deterioration while waiting for NGS report ❗ 3 patients could have been treated with TKIs while waiting for NGS report ❗ 96.4% agreement between Idylla™ and NGS ❗ 10% failure rate on NGS ❗ 82% of failed NGS samples rescued by Idylla™ ❗ 5x less tissue used by Idylla™ vs NGS  ❗ 19.5 days faster reporting with Idylla™ vs NGS 👉 Rapid EGFR Testing with Idylla™ alongside NGS has the potential to enhance lung cancer patient health outcomes 👈 📚 Read the full publication: https://lnkd.in/eWwgKTr5 👀 Check out the publication summary: https://lnkd.in/eBNGkB4v 🕵️♀️ Discover the Idylla™ EGFR Mutation Test (CE-IVD*): https://lnkd.in/dYX7xNeC *Idylla™ EGFR Mutation Test is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, but is for Research Use Only (RUO), not for use in diagnostic procedures, in the US.  #Biocartis #Idylla #LungCancer #NSCLC #EGFR #RapidBiomarkerTesting #BiomarkerTesting #NGS #TKI

Our partner, Geneprodx, has been awarded the 🏆 Best Translational Research Award🏆 by SOCHED for their project "Development and Analytical Performance of the New Automated Idylla™ ThyroidPrint ® Assay to Predict Benignity in Thyroid Nodules with Indeterminate Cytology”! A huge well done to all involved! 👏 🚀 Discover Idylla™ ThyroidPrint ® Assay (RUO*): First-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules 👉 https://lnkd.in/etU7JVTg #Science #Innovation #TranslationalMedicine #ThyroidPrint #SOCHEDAward #Endocrinology #Idylla #Biocartis #GeneproDX * For Research Use Only (RUO), not for use in diagnostic procedures. 🗨 ENGLISH TRANSLATION OF POST: Proud and grateful for this important recognition ✨ We are pleased to announce that we have been awarded the Best Translational Research Award by the Chilean Society of Endocrinology and Diabetes (SOCHED) for our project: “Development and Analytical Performance of the New Automated Idylla™ ThyroidPrint® Assay to Predict Benignity in Thyroid Nodules with Indeterminate Cytology.” This recognition reinforces our commitment to scientific innovation and precision medicine. Our team has worked tirelessly to develop solutions that positively impact patients' lives and facilitate clinical decision-making. This achievement would not have been possible without the dedication of the entire GeneproDX team, our scientific collaborations, and the support of the medical community. We extend our gratitude to SOCHED for this honor, which inspires us to keep advancing in innovative technologies. 👏👏👏 We remain committed to science and patient well-being! 💙🔬

👩⚕️ By analyzing tumor tissue or blood samples, doctors can learn more about a patient’s tumor.  🔎 If certain biomarkers are identified, cancer therapy can be personalized for each patient which often means more effective therapy. ⭐ Idylla™ is a revolutionary, fully automated, molecular testing system designed to offer biomarker results in only 3 hours, shortening the time from sample to treatment initiation to 1 or 2 days. Learn more about Idylla™ 👉 https://lnkd.in/gh9nKbMA #Biocartis #Idylla #PersonalizedMedicine #BiomarkerTesting #Biomarkers

We're #hiring a new Associate Field Service Engineer US in Itasca, Illinois. Apply today or share this post with your network.

We're #hiring a new Procurement Expert in Mechelen, Flemish Region. Apply today or share this post with your network.

🎗️This Breast Cancer Awareness Month, we are excited to introduce 👉 two new innovative molecular diagnostic assays 👈 that mark a significant advancement in biomarker testing in breast cancer! 1️⃣ APIS ESR1 dPCR Kit*: https://lnkd.in/eyVXeaSQ - Wide target coverage: detects 11 ESR1 mutations - High sensitivity & specificity: ≤ 0.1% MAF with no WT detection - Instrument agnostic: compatible with most digital PCR systems 2️⃣ APIS PIK3CA qPCR Kit*: https://lnkd.in/ePH6KFhd - Streamlined workflow: detects > 95% of actionable PIK3CA mutations - High sensitivity: ≤ 0.5% MAF - Multiple sample types: FFPE tumor tissue or plasma 🔍 Discover our Breast Cancer Assay Portfolio: https://lnkd.in/et9_cgFC *Distributed by Biocartis for Research Use Only (RUO), not for use in diagnostic procedures. Data and conclusions have not been validated by Biocartis NV. #Biocartis #Idylla #APIS #ESR1 #PIK3CA #AKT1 #BreastCancerAwarenessMonth #BreastCancer #BreastCancerAwareness #PinkOctober #PinkMonth APIS Assay Technologies Ltd.

Revolutionize your CRC diagnostics with Idylla™ 🏆  ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy. Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay. 👉 Read more https://lnkd.in/eB8vgaVE Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #MSI #RAS #NRAS #KRAS #BRAF #immunotherapy #ColorectalCancer #CRC *Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

📣 PRESS RELEASE 📣 Biocartis announces six Idylla™ abstracts to be presented at Association for Molecular Pathology (AMP) 2024 Annual Meeting Read more 👀 https://lnkd.in/ehR9u6mg #AMP2024 #Idylla #Biocartis #PressRelease

📣 Join us at the Association for Molecular Pathology (AMP) Annual Meeting in Vancouver, Canada (19-23 November)! Stop by booth #825 and learn more about getting your molecular results in ONLY 3 HOURS with Idylla™! ⏱️ Can't get enough? There's more. On Wednesday 20 November, we will also be hosting an AMP workshop. 📖 Same-Day Molecular Testing Results from Cytology Specimens: The Next Frontier of Rapid On-Site Evaluation? Optimizing Small Biopsy Workflows with Idylla™ 📅 Wednesday 20 November, 15:00-15:50 PST 🗣️ Gloria Sura (MD Anderson Cancer Center) Molecular results in only 3 hours! 💡THINK IDYLLA™ Book a meeting with our team now 🤝 https://lnkd.in/e3KWE_9U #AMP2024 #Biocartis #Idylla #ThinkIdylla #Pathology #MolecularDiagnostics

📅 October is Liver Cancer Awareness Month Liver cancer has the 3rd highest mortality rate world wide, with Hepatocellular carcinoma (HCC) being the most common type. Did you know that liver transplantation (LT) is the best curative treatment for HCC patients? 🤔 Unfortunately, it is not always easy to identify which patients should receive LT... 😬 Define the criteria too strictly, you will reject patients that could benefit from LT - define the criteria too loosely, you will overestimate the benefit from a LT for patients who will relapse. ✅ The need for a highly precise and sensitive prognostic tool to identify HCC patients who will benefit from a LT is crucial for improving patient outcomes. Discover Hepatopredict* (CE-IVD) now 👉 https://lnkd.in/escqYpXg *Developed by Ophiomics, distributed by Biocartis. #LiverCancerAwarenessMonth #LCAM #Biocartis #Ophiomics #HepatoPredict #HCC #HepatocellularCarcinoma #LiverCancer #LT #LiverTransplantation